Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Saffron is a spice derived from the dried stigmas of the Crocus sativus flower. It has been used traditionally for its sedative, antidepressant, anti-inflammatory, antioxidant, and potential anticancer properties[2][5]. Saffron contains over 150 chemicals; the most biologically active are crocin and crocetin[7]. Its proposed mechanisms include inhibition of serotonin reuptake in synapses (similar to some antidepressants), modulation of oxidative stress pathways via antioxidant activity, and possible effects on amyloid-beta aggregation relevant to Alzheimer's disease[6][8]. Saffron is primarily cultivated in Iran. It is commonly used as a dietary supplement for depression (mild to moderate), anxiety, premenstrual syndrome (PMS), menstrual cramps, Alzheimer’s disease symptoms, and other conditions; however, robust clinical evidence exists mainly for mild-to-moderate depression and limited improvement in Alzheimer’s symptoms[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on saffron.